SecBot SecBot

MLYS

Mineralys Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001933414 Biotech & Drug Discovery
$15.33 −0.17 (−1.10%)
Nov 13 4:00 PM ET · prev $15.50
Market cap
$1.4B
Small cap
Consensus
Buy
82% Buy or better · 17 analysts
Median target
$52.00
+239% · range $19.00–56.00
1 year
−65.4%
from $44.26 · Nov 17
30 days
−26.7%
from $20.92
52-week range
$15.24–44.26
−65% from high · low Nov 5
Avg volume 20D
2.01M
shares / day
Short interest
7.69M
≈8.7% of shares · +3.4%
Days to cover
5.0
at average volume
Insider net
−$12.5M
0 buyers · 5 sellers · since May 12
New fund stakes
2
Q3 2026 13F · 1 exit
Filing reports
27
analyzed by SecBot
SecBot read BULLISH 13 reports · 90 days
Balance 1 bearish · 3 bullish · 9 neutral oldest → newest, height = score
Avg score ·High conf. 9/13 ·Next FDA decision date, Dec 22, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $12.5M.

  • InstitutionsBULLISH

    Q3 2026: 24 added (2 new), 15 trimmed or exited.

  • AnalystsBULLISH

    14 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.632 → −$0.670 over 90 days. 0 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.4% to 7.69M shares. 5.0 days to cover, ≈8.7% of shares.

  • TrendDOWNTREND

    32% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
1
exit
FundMoveSharesValue
STATE STREET CORPTRIM2,878,520$72.3M
Capital World InvestorsADD2,571,132$64.6M
Aberdeen Group plcADD932,358$23.4M
DIMENSIONAL FUND ADVISORS LPADD651,075$16.4M
Qube Research & Technologies LtdDOUBLED607,421$15.3M
HRT FINANCIAL LPDOUBLED401,849$10.1M
Nuveen, LLCADD371,390$9.3M
BARCLAYS PLCDOUBLED184,015$4.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 82% rate it Buy or better
Strong Buy5Buy9Hold3Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +239%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026UBS
INITIATE
INITIATENeutral
Oct 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$12.5M
sold · 5 insiders
DateInsiderTypeValue
Oct 19, 2026
COATS LONNEL
Director
Oct 19, 2026
AWARD12,400 sh
Oct 19, 2026
Peterson Kristine
Director
Oct 19, 2026
AWARD12,400 sh
Oct 19, 2026
COATS LONNEL
Director
Oct 19, 2026
AWARD16,600 sh
Oct 19, 2026
Peterson Kristine
Director
Oct 19, 2026
AWARD16,600 sh
Sep 30, 2026
Congleton Jon
Chief Executive Officer
Sep 30, 2026
SELL$1.9M
Sep 22, 2026
Slingsby Brian Taylor
Director
Sep 22, 2026
SELL$3.0M
Sep 21, 2026
Warren Eric
Chief Commercial Officer
Sep 21, 2026
EXERCISE$98.5K
Sep 21, 2026
Warren Eric
Chief Commercial Officer
Sep 21, 2026
SELL$209.1K

Earnings setup

Estimates
−$0.67
EPS estimate, this quarter
−6%
estimate change, 90 days
0↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.67-$0.73–-$0.59-13.3%$0.00
Next Q-$0.81-$1.13–-$0.65-4.8%$1.4M
Current FY-$4.59-$4.82–-$4.26-3.7%$0.00
Next FY-$2.60-$3.78–-$1.64-4.2%$79.2M

Short side

FINRA· Oct 30, 2026
7,687,327
shares short
+3.4%
vs prior settlement
5.0
days to cover
≈8.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

SecBot reports

27 filings · 8 press releases · 2 bullish · 2 bearish · 1 mixed · 22 neutral
All MLYS filing & press-release reports (35)